AIM To evaluate the efficacy of direct-acting antivirals(DAAs) in Kanto Rosai Hospital. METHODS All patients with hepatitis C virus(HCV) who underwent DAA prescription were enrolled in this study. The present study wa...AIM To evaluate the efficacy of direct-acting antivirals(DAAs) in Kanto Rosai Hospital. METHODS All patients with hepatitis C virus(HCV) who underwent DAA prescription were enrolled in this study. The present study was a single center retrospective analysis using patients infected with HCV genotype 1 or 2. Resistance analysis was performed by using direct sequencing and cycleave PCR in genotype 1 patients treated with interferon(IFN)-free DAA. The primary endpoint was sustained virologic response at 12 wk after therapy(SVR12).RESULTS A total of 117 patients participated in the study, including 135 with genotype 1 and 42 with genotype 2. Of the 135 patients with genotype 1, 16 received protease inhibitor + IFN + ribavirin and all achieved SVR. Of the 119 patients who received IFN-free DAA(in different combinations), 102 achieved SVR and 9 failed(7/9 were on daclatasvir/asunaprevir and 2/9 on ledipasvir/sofosbuvir). Efficacy analysis was done only for 43 patients who received daclatasvir/asunaprevir. From this analysis, Y93 resistance-associated substitutions were significantly correlated with SVR.CONCLUSION The SVR rate was 98% for genotype 1 and 100% for genotype 2. However, caution is needed for HCV NS5 A resistance-associated substitutions that are selected by HCV NS5 A inhibitors because cerebrovascular adverse events are induced by some DAA drugs.展开更多
基金Supported by research funds to promote the Hospital functions of the Japan Organization of Occupational Health and SafetyNo.359
文摘AIM To evaluate the efficacy of direct-acting antivirals(DAAs) in Kanto Rosai Hospital. METHODS All patients with hepatitis C virus(HCV) who underwent DAA prescription were enrolled in this study. The present study was a single center retrospective analysis using patients infected with HCV genotype 1 or 2. Resistance analysis was performed by using direct sequencing and cycleave PCR in genotype 1 patients treated with interferon(IFN)-free DAA. The primary endpoint was sustained virologic response at 12 wk after therapy(SVR12).RESULTS A total of 117 patients participated in the study, including 135 with genotype 1 and 42 with genotype 2. Of the 135 patients with genotype 1, 16 received protease inhibitor + IFN + ribavirin and all achieved SVR. Of the 119 patients who received IFN-free DAA(in different combinations), 102 achieved SVR and 9 failed(7/9 were on daclatasvir/asunaprevir and 2/9 on ledipasvir/sofosbuvir). Efficacy analysis was done only for 43 patients who received daclatasvir/asunaprevir. From this analysis, Y93 resistance-associated substitutions were significantly correlated with SVR.CONCLUSION The SVR rate was 98% for genotype 1 and 100% for genotype 2. However, caution is needed for HCV NS5 A resistance-associated substitutions that are selected by HCV NS5 A inhibitors because cerebrovascular adverse events are induced by some DAA drugs.
